



## **LB Pharmaceuticals To Participate in the B. Riley Securities' Neuroscience Conference**

**New York, NY (April 26, 2021)** – LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today that Zachary Prensky, President and Chief Executive Officer, will present at the 2021 B. Riley Securities' Neuroscience Conference, to be held virtually on April 28-29, 2021.

LB's presentation will take place on Thursday, April 29<sup>th</sup> at 9:30am ET and will be live webcast to registered attendees at <https://www.webcaster4.com/Webcast/Page/2433/41078>. Following the presentation, Mr. Prensky will participate in a question-and-answer session. After completion of the event, a replay of the presentation will be publicly available on the LB website at [www.lbpharma.us/presentations](http://www.lbpharma.us/presentations).

### **About LB Pharmaceuticals**

LB is a development stage CNS-focused life science company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed, in the United States. Our approach is to create a research-focused organization dedicated to generating novel intellectual property around improved versions of these former best-selling drugs. We have a low-risk, high-reward drug development business plan: Invest in bringing to the US market patented, branded, first-to-market versions of standard-of-care CNS therapies currently in use worldwide.

LB's lead compound, LB-102, or *N*-methyl amisulpride, is a patented benzamide designed to be an improved version of amisulpride, a dopamine/5-HT<sub>7</sub> antagonist successfully used to treat schizophrenia in Europe for decades. LB-102 was designed to improve on amisulpride's low permeability across the blood brain barrier. LB-102 has the potential to offer schizophrenia patients the benefits of amisulpride at a lower dose than amisulpride. A first-in-human, double-blind placebo-controlled Phase 1 study designed to test the safety and pharmacokinetics of LB-102 was completed over the summer of 2020. A Phase 2 clinical trial in acute schizophrenia patients is expected to commence in the fourth quarter of 2021.

More information about LB-102 and LB Pharmaceuticals may be found on our corporate website located at [www.LBPharma.us](http://www.LBPharma.us)

### **Contact**

Zachary Prensky, President & CEO  
[Zach@LBPharma.us](mailto:Zach@LBPharma.us) (212) 605-0230  
575 Madison Avenue, 10<sup>th</sup> Floor  
New York, NY 10022